Skip to main content
SpringerLink
Log in

Live Attenuated Vaccines: Influenza, Rotavirus and Varicella Zoster Virus

  • Chapter
  • First Online:
Book cover Replicating Vaccines

Part of the book series: Birkhäuser Advances in Infectious Diseases ((BAID))

Abstract

Since vaccinia virus was first used to protect against smallpox in the eighteenth century, live attenuated vaccines have proved to be highly effective in reducing the morbidity and mortality caused by many human viral pathogens. Contemporary live viral vaccines are designed using several different strategies to achieve attenuation. These basic principles and approaches are illustrated by vaccines to prevent rotavirus, influenza and varicella-zoster virus infections that are described in this chapter. As shown from the experience with these three vaccines, contemporary live attenuated viral vaccines have had a major impact on disease caused by these ubiquitous human pathogens.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. (2004) Update: influenza-associated deaths reported among children aged <18 years – United States, 2003-04 influenza season. MMWR Morb Mortal Wkly Rep 52: 1286–1288

    Google Scholar 

  2. Wright PF, Neumann G, Kawaoka Y (2007) Orthomyxovirus. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott, Philadelphia

    Google Scholar 

  3. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI et al (2000) Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181:1133–1137

    CAS  PubMed  Google Scholar 

  4. Lee MS, Mahmood K, Adhikary L, August MJ, Cordova J, Cho I, Kemble G, Reisinger K, Walker RE, Mendelman PM (2004) Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr Infect Dis J 23:852–856

    PubMed  Google Scholar 

  5. Mendelman PM, Rappaport R, Cho I, Block S, Gruber W, August M, Dawson D, Cordova J, Kemble G, Mahmood K et al (2004) Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr Infect Dis J 23:1053–1055

    PubMed  Google Scholar 

  6. Sasaki S, He XS, Holmes TH, Dekker CL, Kemble GW, Arvin AM, Greenberg HB (2008) Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 3:e2975

    PubMed  Google Scholar 

  7. Sasaki S, Jaimes MC, Holmes TH, Dekker CL, Mahmood K, Kemble GW, Arvin AM, Greenberg HB (2007) Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 81:215–228

    CAS  PubMed  Google Scholar 

  8. Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, Rappaport R, Eldridge JH, Gruber WC (2008) Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 15:1042–1053

    CAS  PubMed  Google Scholar 

  9. He XS, Holmes TH, Mahmood K, Kemble GW, Dekker CL, Arvin AM, Greenberg HB (2008) Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J Infect Dis 197:803–811

    CAS  PubMed  Google Scholar 

  10. He XS, Holmes TH, Sasaki S, Jaimes MC, Kemble GW, Dekker CL, Arvin AM, Greenberg HB (2008) Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. PLoS One 3:e2574

    PubMed  Google Scholar 

  11. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, Dekker CL, Greenberg HB, Arvin AM (2006) Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 80:11756–11766

    CAS  PubMed  Google Scholar 

  12. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, Glezen WP, Wittes J (1999) Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282:137–144

    CAS  PubMed  Google Scholar 

  13. Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, Wittes J, Bryant M (1999) Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18:899–906

    CAS  PubMed  Google Scholar 

  14. Maassab HF (1968) Plaque formation of influenza virus at 25 degrees C. Nature 219:645–646

    CAS  PubMed  Google Scholar 

  15. Maassab HF, Francis T Jr, Davenport FM, Hennessy AV, Minuse E, Anderson G (1969) Laboratory and clinical characteristics of attenuated strains of influenza virus. Bull World Health Organ 41:589–594

    CAS  PubMed  Google Scholar 

  16. Jin H, Lu B, Zhou H, Ma C, Zhao J, Yang CF, Kemble G, Greenberg H (2003) Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 306:18–24

    CAS  PubMed  Google Scholar 

  17. Chen Z, Aspelund A, Kemble G, Jin H (2006) Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (FluMist). Virology 345:416–423

    CAS  PubMed  Google Scholar 

  18. Hoffmann E, Mahmood K, Chen Z, Yang CF, Spaete J, Greenberg HB, Herlocher ML, Jin H, Kemble G (2005) Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66. J Virol 79:11014–11021

    CAS  PubMed  Google Scholar 

  19. Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpaa R, Salmi A, Saville MK, Cho I, Razmpour A, Rappaport R et al (2006) A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 25:590–595

    PubMed  Google Scholar 

  20. Buonagurio DA, O'Neill RE, Shutyak L, D'Arco GA, Bechert TM, Kazachkov Y, Wang HP, DeStefano J, Coelingh KL, August M et al (2006) Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. Virology 347:296–306

    CAS  PubMed  Google Scholar 

  21. Murphy BR, Coelingh K (2002) Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 15:295–323

    CAS  PubMed  Google Scholar 

  22. Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kuhr J, Bujnowski T, Desgrandchamps D et al (2006) Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 25:870–879

    PubMed  Google Scholar 

  23. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM (2007) Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356:685–696

    CAS  PubMed  Google Scholar 

  24. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacuzio D, Piedra P, Treanor J et al (2000) Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136:168–175

    CAS  PubMed  Google Scholar 

  25. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K et al (1998) The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 338:1405–1412

    CAS  PubMed  Google Scholar 

  26. Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, Small MG, Gruber WC, Forrest BD (2009) Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 28:365–371

    PubMed  Google Scholar 

  27. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Oymar K, Garcia ML, Krygier A, Costa H et al (2006) Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 25:860–869

    PubMed  Google Scholar 

  28. Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J (2009) Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine 27:1101–1110

    CAS  PubMed  Google Scholar 

  29. Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S et al (2007) Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 26:619–628

    PubMed  Google Scholar 

  30. Vesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R, Skinner J, Saville MK, Gruber WC, Forrest BD (2006) Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 118:2298–2312

    PubMed  Google Scholar 

  31. Block SL, Toback SL, Yi T, Ambrose CS (2009) Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years. Clin Ther 31:2140–2147

    PubMed  Google Scholar 

  32. De Villiers PJ, Steele AD, Hiemstra LA, Rappaport R, Dunning AJ, Gruber WC, Forrest BD (2009) Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 28:228–234

    PubMed  Google Scholar 

  33. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC (2009) Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 361:1260–1267

    CAS  PubMed  Google Scholar 

  34. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, Monto AS (2006) Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 355:2513–2522

    CAS  PubMed  Google Scholar 

  35. Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, Newton DW, Campbell SA, Boulton ML, Monto AS (2008) Prevention of symptomatic seasonal influenza in 2005–2006 by inactivated and live attenuated vaccines. J Infect Dis 198:312–317

    PubMed  Google Scholar 

  36. Eick AA, Wang Z, Hughes H, Ford SM, Tobler SK (2009) Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. Vaccine 27:3568–3575

    CAS  PubMed  Google Scholar 

  37. Wang Z, Tobler S, Roayaei J, Eick A (2009) Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 301:945–953

    CAS  PubMed  Google Scholar 

  38. Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, Walker R, Hessel C, Cordova J, Mendelman PM (2004) Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 23:138–144

    PubMed  Google Scholar 

  39. Bishop RF, Davidson GP, Holmes IH, Ruck BJ (1973) Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 2:1281–1283

    CAS  PubMed  Google Scholar 

  40. Franco MA, Greenberg H (2008) Rotaviruses. In: Richman D, Hayden F, Whitley R (eds) Clinical Virology. ASM Press, Washington DC

    Google Scholar 

  41. (2008) Rotavirus surveillance--worldwide, 2001-2008. MMWR Morb Mortal Wkly Rep 1255–1257

    Google Scholar 

  42. Payne DC, Staat MA, Edwards KM, Szilagyi PG, Gentsch JR, Stockman LJ, Curns AT, Griffin M, Weinberg GA, Hall CB et al (2008) Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States. Pediatrics 122:1235–1243

    PubMed  Google Scholar 

  43. Parashar UD, Gibson CJ, Bresse JS, Glass RI (2006) Rotavirus and severe childhood diarrhea. Emerg Infect Dis 12:304–306

    PubMed  Google Scholar 

  44. Turcios RM, Curns AT, Holman RC, Pandya-Smith I, LaMonte A, Bresee JS, Glass RI (2006) Temporal and geographic trends of rotavirus activity in the United States, 1997-2004. Pediatr Infect Dis J 25:451–454

    PubMed  Google Scholar 

  45. Atchison C, BChir MB, Iturriza-Gomara M, Tam C, Lopman B (2010) Spatiotemporal dynamics of rotavirus disease in Europe: can climate or demographic variability explain the patterns observed. Pediatr Infect Dis J 29:566–568

    PubMed  Google Scholar 

  46. Pitzer VE, Viboud C, Simonsen L, Steiner C, Panozzo CA, Alonso WJ, Miller MA, Glass RI, Glasser JW, Parashar UD et al (2009) Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 325:290–294

    CAS  PubMed  Google Scholar 

  47. Levy K, Hubbard AE, Eisenberg JN (2009) Seasonality of rotavirus disease in the tropics: a systematic review and meta-analysis. Int J Epidemiol 38:1487–1496

    PubMed  Google Scholar 

  48. Nakagomi O, Cunliffe NA (2007) Rotavirus vaccines: entering a new stage of deployment. Curr Opin Infect Dis 20:501–507

    PubMed  Google Scholar 

  49. Santos N, Hoshino Y (2005) Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 15:29–56

    PubMed  Google Scholar 

  50. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, Glass RI, Estes MK, Pickering LK, Ruiz-Palacios GM (1996) Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 335:1022–1028

    CAS  PubMed  Google Scholar 

  51. Blutt SE, Matson DO, Crawford SE, Staat MA, Azimi P, Bennett BL, Piedra PA, Conner ME (2007) Rotavirus antigenemia in children is associated with viremia. PLoS Med 4:e121

    PubMed  Google Scholar 

  52. Corthesy B, Benureau Y, Perrier C, Fourgeux C, Parez N, Greenberg H, Schwartz-Cornil I (2006) Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol 80:10692–10699

    CAS  PubMed  Google Scholar 

  53. Franco MA, Angel J, Greenberg HB (2006) Immunity and correlates of protection for rotavirus vaccines. Vaccine 24:2718–2731

    CAS  PubMed  Google Scholar 

  54. Coulson BS, Grimwood K, Hudson IL, Barnes GL, Bishop RF (1992) Role of coproantibody in clinical protection of children during reinfection with rotavirus. J Clin Microbiol 30:1678–1684

    CAS  PubMed  Google Scholar 

  55. Chiba S, Nakata S, Ukae S, Adachi N (1993) Virological and serological aspects of immune resistance to rotavirus gastroenteritis. Clin Infect Dis 16(Suppl 2):S117–S121

    PubMed  Google Scholar 

  56. Green KY, Taniguchi K, Mackow ER, Kapikian AZ (1990) Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. J Infect Dis 161:667–679

    CAS  PubMed  Google Scholar 

  57. Ward RL, Kirkwood CD, Sander DS, Smith VE, Shao M, Bean JA, Sack DA, Bernstein DI (2006) Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12. J Infect Dis 194:1729–1736

    CAS  PubMed  Google Scholar 

  58. Zhang W, Azevedo MS, Wen K, Gonzalez A, Saif LJ, Li G, Yousef AE, Yuan L (2008) Probiotic Lactobacillus acidophilus enhances the immunogenicity of an oral rotavirus vaccine in gnotobiotic pigs. Vaccine 26:3655–3661

    CAS  PubMed  Google Scholar 

  59. Wang Y, Dennehy PH, Keyserling HL, Tang K, Gentsch JR, Glass RI, Jiang B (2007) Rotavirus infection alters peripheral T-cell homeostasis in children with acute diarrhea. J Virol 81:3904–3912

    CAS  PubMed  Google Scholar 

  60. Guarino A, Lo Vecchio A, Canani RB (2009) Probiotics as prevention and treatment for diarrhea. Curr Opin Gastroenterol 25:18–23

    PubMed  Google Scholar 

  61. Graff JW, Mitzel DN, Weisend CM, Flenniken ML, Hardy ME (2002) Interferon regulatory factor 3 is a cellular partner of rotavirus NSP1. J Virol 76:9545–9550

    CAS  PubMed  Google Scholar 

  62. Barro M, Patton JT (2007) Rotavirus NSP1 inhibits expression of type I interferon by antagonizing the function of interferon regulatory factors IRF3, IRF5, and IRF7. J Virol 81:4473–4481

    CAS  PubMed  Google Scholar 

  63. Graff JW, Ettayebi K, Hardy ME (2009) Rotavirus NSP1 inhibits NFkappaB activation by inducing proteasome-dependent degradation of beta-TrCP: a novel mechanism of IFN antagonism. PLoS Pathog 5:e1000280

    PubMed  Google Scholar 

  64. Feng N, Kim B, Fenaux M, Nguyen H, Vo P, Omary MB, Greenberg HB (2008) Role of interferon in homologous and heterologous rotavirus infection in the intestines and extraintestinal organs of suckling mice. J Virol 82:7578–7590

    CAS  PubMed  Google Scholar 

  65. Heaton PM, Ciarlet M (2007) Vaccines: the pentavalent rotavirus vaccine: discovery to licensure and beyond. Clin Infect Dis 45:1618–1624

    PubMed  Google Scholar 

  66. Vesikari T (2008) Rotavirus vaccines. Scand J Infect Dis 40:691–695

    CAS  PubMed  Google Scholar 

  67. Dennehy PH (2008) Rotavirus vaccines: an overview. Clin Microbiol Rev 21:198–208

    CAS  PubMed  Google Scholar 

  68. Kapikian AZ, Hoshino Y, Chanock RM, Perez-Schael I (1996) Jennerian and modified Jennerian approach to vaccination against rotavirus diarrhea using a quadrivalent rhesus rotavirus (RRV) and human-RRV reassortant vaccine. Arch Virol Suppl 12:163–175

    CAS  PubMed  Google Scholar 

  69. Sen A, Feng N, Ettayebi K, Hardy ME, Greenberg HB (2009) IRF3 inhibition by rotavirus NSP1 is host cell and virus strain dependent but independent of NSP1 proteasomal degradation. J Virol 83:10322–10335

    CAS  PubMed  Google Scholar 

  70. Patel NC, Hertel PM, Estes MK, de la Morena M, Petru AM, Noroski LM, Revell PA, Hanson IC, Paine ME, Rosenblatt HM et al (2010) Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 362:314–319

    CAS  PubMed  Google Scholar 

  71. Patel MM, Haber P, Baggs J, Zuber P, Bines JE, Parashar UD (2009) Intussusception and rotavirus vaccination: a review of the available evidence. Expert Rev Vaccines 8:1555–1564

    PubMed  Google Scholar 

  72. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, Esparza-Aguilar M, Johnson B, Gomez ACM, Parashar U, Patel M (2010) Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 362:299–305

    CAS  PubMed  Google Scholar 

  73. Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD (2010) Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 125:e208–e213

    PubMed  Google Scholar 

  74. Boom JA, Tate JE, Sahni LC, Rench MA, Hull JJ, Gentsch JR, Patel MM, Baker CJ, Parashar UD (2010) Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Am Acad Pediatr 125(2):e199–e207

    Google Scholar 

  75. Committee on Infectious Diseases (2009) Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics 123:1412–1420

    Google Scholar 

  76. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB et al (2010) Effect of human rotavirus vaccine on severe diarrhea in african infants. N Engl J Med 362:289–298

    CAS  PubMed  Google Scholar 

  77. Bhandari N, Sharma P, Taneja S, Kumar T, Rongsen-Chandola T, Appaiahgari MB, Mishra A, Singh S, Vrati S (2009) A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. J Infect Dis 200:421–429

    CAS  PubMed  Google Scholar 

  78. Cohen JI, Strauss SE, Arvin AM (2007) Varicella-Zoster Virus. In: Knipe DM (ed) Fields virology. Lippincott Williams and Wilkins Press, Philadelphia, pp 2773–2818

    Google Scholar 

  79. Arvin AM (2001) Varicella vaccine: genesis, efficacy, and attenuation. Virology 284:153–158

    CAS  PubMed  Google Scholar 

  80. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ (2000) Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 342:635–645

    CAS  PubMed  Google Scholar 

  81. Breuer J (2010) VZV molecular epidemiology. Cur Top Microbiol Immunol

    Google Scholar 

  82. McGeoch DJ (2009) Lineages of varicella-zoster virus. J Gen Virol 90:963–969

    CAS  PubMed  Google Scholar 

  83. Peters GA, Tyler SD, Grose C, Severini A, Gray MJ, Upton C, Tipples GA (2006) A full-genome phylogenetic analysis of varicella-zoster virus reveals a novel origin of replication-based genotyping scheme and evidence of recombination between major circulating clades. J Virol 80:9850–9860

    CAS  PubMed  Google Scholar 

  84. Davison AJ, Scott JE (1986) The complete DNA sequence of varicella-zoster virus. J Gen Virol 67(9):1759–1816

    CAS  PubMed  Google Scholar 

  85. Seward JF, Marin M, Vazquez M (2008) Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis 197(Suppl 2):S82–S89

    PubMed  Google Scholar 

  86. Ku CC, Besser J, Abendroth A, Grose C, Arvin AM (2005) Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol 79:2651–2658

    CAS  PubMed  Google Scholar 

  87. Zerboni L, Arvin AM (2008) The pathogenesis of varicella zoater virus neurotropism and infection. In: Reiss C (ed) Neurotropci viral infections. Cambridge Press, New York, pp 225–250

    Google Scholar 

  88. Ku CC, Zerboni L, Ito H, Graham BS, Wallace M, Arvin AM (2004) Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med 200:917–925

    CAS  PubMed  Google Scholar 

  89. Gershon AA, Chen J, Davis L, Krinsky C, Cowles R, Gershon MD (2009) Distribution of latent varicella zoster virus in sensory ganglia and gut after vaccination and wild-type infection: evidence for viremic spread. 34th International Herpesvirus Workshop, Ithaca, NY

    Google Scholar 

  90. Zerboni L, Ku CC, Jones CD, Zehnder JL, Arvin AM (2005) Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proc Natl Acad Sci USA 102:6490–6495

    CAS  PubMed  Google Scholar 

  91. Reichelt M, Zerboni L, Arvin AM (2008) Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J Virol 82:3971–3983

    CAS  PubMed  Google Scholar 

  92. Arvin AM (2008) Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis 197(Suppl 2):S58–S60

    CAS  PubMed  Google Scholar 

  93. Arvin AM, Koropchak CM, Williams BR, Grumet FC, Foung SK (1986) Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis 154:422–429

    CAS  PubMed  Google Scholar 

  94. Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H et al (2009) Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 200:1068–1077

    CAS  PubMed  Google Scholar 

  95. Wallace MR, Chamberlin CJ, Zerboni L, Sawyer MH, Oldfield EC, Olson PE, Arvin AM (1997) Reliability of a history of previous varicella infection in adults. JAMA 278:1520–1522

    CAS  PubMed  Google Scholar 

  96. Taha YA, Quinlivan M, Scott FT, Leedham-Green M, Hawrami K, Thomas JM, Breuer J (2004) Are false negative direct immnufluorescence assays caused by varicella zoster virus gE mutant strains? J Med Virol 73:631–635

    CAS  PubMed  Google Scholar 

  97. Vleck SE, Oliver SL, Reichelt M, Rajamani J, Zerboni L, Jones C, Zehnder J, Grose C, Arvin AM (2010) Anti-glycoprotein H antibody impairs the pathogenicity of varicella-zoster virus in skin xenografts in the SCID mouse model. J Virol 84:141–152

    CAS  PubMed  Google Scholar 

  98. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J et al (2008) Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 197:825–835

    CAS  PubMed  Google Scholar 

  99. Gershon A, Takahashi M, Seward J (2008) Live attenuated varicella vaccine. In: Plotkin S, Orenstein W, Offit P (eds) Vaccines. W.B. Saunders, Philadelphia, pp 915–958

    Google Scholar 

  100. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2:1288–1290

    CAS  PubMed  Google Scholar 

  101. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, Arvin AM (2002) Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 347:26–34

    PubMed  Google Scholar 

  102. Loparev VN, Rubtcova EN, Bostik V, Govil D, Birch CJ, Druce JD, Schmid DS, Croxson MC (2007) Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand. J Virol 81:12758–12765

    CAS  PubMed  Google Scholar 

  103. Quinlivan MA, Gershon AA, Nichols RA, La Russa P, Steinberg SP, Breuer J (2006) Vaccine Oka varicella-zoster virus genotypes are monomorphic in single vesicles and polymorphic in respiratory tract secretions. J Infect Dis 193:927–930

    CAS  PubMed  Google Scholar 

  104. Sauerbrei A, Zell R, Philipps A, Wutzler P (2008) Genotypes of varicella-zoster virus wild-type strains in Germany. J Med Virol 80:1123–1130

    CAS  PubMed  Google Scholar 

  105. Arvin AM, Schaap AC, Ku C-C, Jones JO, Sommer M, Zerboni Z (2006) Investigations of the molecular mechanisms of varicella-zoster virus pathogenesis. In: Sandri-Golden R (ed) The Alphaherpesviruses. Horizon Press Inc, UK

    Google Scholar 

  106. Hambleton S, Steinberg SP, Larussa PS, Shapiro ED, Gershon AA (2008) Risk of herpes zoster in adults immunized with varicella vaccine. J Infect Dis 197(Suppl 2):S196–S199

    PubMed  Google Scholar 

  107. Levin MJ, DeBiasi RL, Bostik V, Schmid DS (2008) Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella-zoster virus vaccine. J Infect Dis 198:1444–1447

    PubMed  Google Scholar 

  108. Zerboni L, Hinchliffe S, Sommer MH, Ito H, Besser J, Stamatis S, Cheng J, Distefano D, Kraiouchkine N, Shaw A et al (2005) Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology 332:337–346

    CAS  PubMed  Google Scholar 

  109. Schmid DS (2010) VZV vaccine: Molecular genetics. In: A Abendroth, AM Arvin, J Moffat (eds) Varicella-zoster virus. Curr Top Microbiol Immunol Elsevier Inc.

    Google Scholar 

  110. Czajka H, Schuster V, Zepp F, Esposito S, Douha M, Willems P (2009) A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine 27:6504–6511

    CAS  PubMed  Google Scholar 

  111. Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, Xu J, Hartzel J, Evans B, Digilio L et al (2006) Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatr Infect Dis J 25:287–292

    PubMed  Google Scholar 

  112. Levin MJ (2008) Zoster vaccine. In: Plotkin S, Orenstein W, Offit PA (eds) Vaccines. W.B. Saunders, Philadelphia, pp 1057–1068

    Google Scholar 

  113. Hayward AR, Buda K, Levin MJ (1994) Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral Immunol 7:31–36

    CAS  PubMed  Google Scholar 

  114. Bonanni P, Breuer J, Gershon A, Gershon M, Hryniewicz W, Papaevangelou V, Rentier B, Rumke H, Sadzot-Delvaux C, Senterre J et al (2009) Varicella vaccination in Europe – taking the practical approach. BMC Med 7:26

    PubMed  Google Scholar 

  115. Nguyen HQ, Jumaan AO, Seward JF (2005) Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 352:450–458

    CAS  PubMed  Google Scholar 

  116. Prevention CfDCa (2007) Prevention of varicella. Morbidity Report Wkly Rep 1–55

    Google Scholar 

  117. Chaves SS, Gargiullo P, Zhang JX, Civen R, Guris D, Mascola L, Seward JF (2007) Loss of vaccine-induced immunity to varicella over time. N Engl J Med 356:1121–1129

    CAS  PubMed  Google Scholar 

  118. Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, Reisinger K, Kim LL, Lupinacci L, Hartzel J et al (2004) Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 23:132–137

    PubMed  Google Scholar 

  119. Michalik DE, Steinberg SP, Larussa PS, Edwards KM, Wright PF, Arvin AM, Gans HA, Gershon AA (2008) Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis 197:944–949

    PubMed  Google Scholar 

  120. Chaves SS, Haber P, Walton K, Wise RP, Izurieta HS, Schmid DS, Seward JF (2008) Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. J Infect Dis 197(Suppl 2):S170–S177

    PubMed  Google Scholar 

  121. Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, Gershon AA, Sharrar RG (2008) The safety profile of varicella vaccine: a 10-year review. J Infect Dis 197(Suppl 2):S165–S169

    PubMed  Google Scholar 

  122. Breuer J, Schmid DS (2008) Vaccine Oka variants and sequence variability in vaccine-related skin lesions. J Infect Dis 197(Suppl 2):S54–S57

    PubMed  Google Scholar 

  123. Quinlivan ML, Gershon AA, Al Bassam MM, Steinberg SP, LaRussa P, Nichols RA, Breuer J (2007) Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts. Proc Natl Acad Sci USA 104:208–212

    CAS  PubMed  Google Scholar 

  124. Civen R, Chaves SS, Jumaan A, Wu H, Mascola L, Gargiullo P, Seward JF (2009) The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J 28:954–959

    PubMed  Google Scholar 

  125. Tseng HF, Smith N, Marcy SM, Sy LS, Jacobsen SJ (2009) Incidence of herpes zoster among children vaccinated with varicella vaccine in a prepaid health care plan in the United States, 2002-2008. Pediatr Infect Dis J 28:1069–1072

    PubMed  Google Scholar 

  126. Prevention CfDCa (2008) Prevention of herpes Zoster: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 779

    Google Scholar 

  127. Gershon AA, Levin MJ, Weinberg A, Song LY, LaRussa PS, Steinberg SP, Bartlett P (2009) A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J 28:653–655

    PubMed  Google Scholar 

  128. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE et al (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271–2284

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Joseph D. Grant Medicine and Microbiology & Immunology, Stanford University School of Medicine, 291 Campus Drive LKSC Bldg Room LD3C02, Stanford, CA, 94305-5101, USA

    Harry B. Greenberg

  2. Departments of Medicine, Pediatrics and Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA

    Ann M. Arvin

Authors
  1. Harry B. Greenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ann M. Arvin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harry B. Greenberg .

Editor information

Editors and Affiliations

  1. Novartis Vaccines & Diagnostics, Sydney St. 45, Cambridge, 02139, Massachusetts, USA

    Philip R. Dormitzer

  2. Novartis Vaccines & Diagnostics, Inc., Massachusetts Ave. 350, Cambridge, 02139, Massachusetts, USA

    Christian W. Mandl

  3. Novartis Vaccines & Diagnostics S.r.l., Via Fiorentina 1, Siena, 53100, Italy

    Rino Rappuoli

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Basel

About this chapter

Cite this chapter

Greenberg, H.B., Arvin, A.M. (2011). Live Attenuated Vaccines: Influenza, Rotavirus and Varicella Zoster Virus. In: Dormitzer, P., Mandl, C., Rappuoli, R. (eds) Replicating Vaccines. Birkhäuser Advances in Infectious Diseases. Springer, Basel. https://doi.org/10.1007/978-3-0346-0277-8_2

Download citation

Publish with us

Policies and ethics

Search

Navigation